Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by LMR Partners LLP

LMR Partners LLP lifted its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 145.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 82,479 shares of the company's stock after purchasing an additional 48,920 shares during the period. LMR Partners LLP owned 0.12% of Replimune Group worth $904,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Price T Rowe Associates Inc. MD boosted its stake in Replimune Group by 12.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company's stock worth $53,505,000 after purchasing an additional 699,679 shares in the last quarter. Millennium Management LLC raised its stake in Replimune Group by 575.1% in the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company's stock worth $28,062,000 after buying an additional 2,656,173 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Replimune Group by 1.2% during the first quarter. Vanguard Group Inc. now owns 2,770,328 shares of the company's stock valued at $22,634,000 after acquiring an additional 32,555 shares in the last quarter. Clearbridge Investments LLC lifted its holdings in Replimune Group by 2.7% in the first quarter. Clearbridge Investments LLC now owns 277,969 shares of the company's stock valued at $2,271,000 after acquiring an additional 7,274 shares during the period. Finally, TD Asset Management Inc increased its position in shares of Replimune Group by 4.6% during the second quarter. TD Asset Management Inc now owns 249,940 shares of the company's stock worth $2,249,000 after purchasing an additional 11,094 shares in the last quarter. Institutional investors own 92.53% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on REPL shares. JPMorgan Chase & Co. raised their target price on shares of Replimune Group from $14.00 to $17.00 and gave the company an "overweight" rating in a report on Tuesday, September 24th. Roth Mkm assumed coverage on shares of Replimune Group in a report on Tuesday, August 27th. They issued a "buy" rating and a $17.00 price objective on the stock. Roth Capital raised shares of Replimune Group to a "strong-buy" rating in a research report on Tuesday, August 27th. Finally, HC Wainwright restated a "buy" rating and issued a $17.00 price objective on shares of Replimune Group in a research report on Tuesday, November 12th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $16.80.

Replimune Group Trading Up 2.6 %

REPL traded up $0.28 during trading on Wednesday, reaching $11.23. The company had a trading volume of 548,279 shares, compared to its average volume of 1,032,710. The company has a quick ratio of 10.11, a current ratio of 10.11 and a debt-to-equity ratio of 0.18. The stock has a market cap of $768.36 million, a P/E ratio of -3.68 and a beta of 1.19. The business has a 50 day simple moving average of $11.48 and a 200-day simple moving average of $9.64. Replimune Group, Inc. has a 52 week low of $4.92 and a 52 week high of $12.97.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, topping analysts' consensus estimates of ($0.75) by $0.07. On average, equities analysts anticipate that Replimune Group, Inc. will post -3.02 EPS for the current fiscal year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.